Avui, dilluns 8 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
Hoy, lunes 8 de junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Today, Monday, Jun 8th, the Digital Repository will be unavailable due to a system update.

Files

700167.pdf (1.67 MB)

Document type

Article

Version

Published version

Publication date

2019-10-31

Publication license

cc-by-nc-nd (c) Torres et. al. , 2019
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/171086

Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1080/13696998.2019.1688819

Abstract

Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.

Subject

Pneumònia adquirida a la comunitat, Antibiòtics

Subject (English)

Community-acquired pneumonia, Antibiotics

Citation

Collections

Articles publicats en revistes (Medicina)

Citation

TORRES MARTÍ, Antoni, et al. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Media Economics. 2019. Vol. 23, num. 2, pags. 148-155. ISSN 0899-7764. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/171086

Export metadata

JSON - METS

Share record